1. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. (5th November 2016) Authors: de Greef, R; Elassaiss‐Schaap, J; Chatterjee, M; Turner, DC; Ahamadi, M; Forman, M; Cutler, D; de Alwis, DP; Kondic, A; Stone, J Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma. (29th November 2016) Authors: Chatterjee, MS; Elassaiss‐Schaap, J; Lindauer, A; Turner, DC; Sostelly, A; Freshwater, T; Mayawala, K; Ahamadi, M; Stone, JA; de Greef, R; Kondic, AG; de Alwis, DP Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma. (14th April 2016) Authors: Daryani, VM; Patel, YT; Tagen, M; Turner, DC; Carcaboso, AM; Atkinson, JM; Gajjar, A; Gilbertson, RJ; Wright, KD; Stewart, CF Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 5:Number 4(2016:Apr.) Page Start: 211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗